Iodură De Potasiu Serb (Potassium Iodide)

Potassium iodide supplies stable iodide ions that compete with radioactive iodine for the sodium‑iodide symporter in thyroid cells. By saturating the gland with non‑radioactive iodide, it limits the amount of radioactive iodine that can be absorbed, thereby protecting the thyroid from radiation damage.

The appropriate dose of Iodură De Potasiu Serb is determined by a qualified healthcare professional based on the specific indication, the level of exposure, age, weight, and individual health status. Prescribers follow national or international guidelines to set the correct regimen.

Safety data for potassium iodide in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified clinician after evaluating the clinical situation.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Potassium iodide is the most widely used and studied thyroid blocking agent because of its rapid onset, oral availability, and well‑characterised safety profile. Alternatives such as perchlorate or thiocyanate are less commonly employed due to lower efficacy and higher risk of adverse effects.

The product should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Proper storage helps maintain the stability of the iodide ions and ensures the medication remains effective until its expiry date.

Iodură De Potasiu Serb is taken orally, usually as a tablet or liquid preparation, as directed by a healthcare professional. The dose is typically administered once, with or without food, depending on the specific clinical protocol.

Serious risks include severe allergic reactions such as anaphylaxis, significant thyroid dysfunction (hypo‑ or hyperthyroidism), and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for any signs of these conditions, especially after high‑dose or repeated administration.

Individuals with known hypersensitivity to potassium iodide, those with uncontrolled thyroid disorders, and patients on certain interacting medications (e.g., thionamides, lithium) should avoid using the product unless a physician determines that benefits outweigh the risks.